HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SOUTH AFRICA

CURRENT SITUATION AND INTERNATIONAL TRENDS

8-9 October 2019

Local and international experts, together with key stakeholders, will review pharmacoeconomic cost-effectiveness and health technology assessment (HTA) methodologies and their application, and discuss barriers to HTA implementation in South Africa and to availability of essential medicines. Based on needs and expectations, suggestions will be proposed for the way forward. This workshop provides an opportunity for networking between different groups affected by HTA of medicines, and for knowledge dissemination.

PROGRAMME COMMITTEE:

Ntobeko Mpanza, BPharm, MSc

Director, Pharmaceutical Economic Evaluations
Directorate, National Department of Health, South
Africa

Prof Bernd Rosenkranz, MD, PhD (Germany), FFPM

President, Fundisa African Academy of Medicines Development, Cape Town and Professor emeritus, Division of Clinical Pharmacology, Stellenbosch University

Tommy Wilkinson, BPharm, MSc Health Economics

Health Economics Unit (HEU), University of Cape Town and chairperson of the Pharmacoeconomics Task Team, Pricing Committee

SPEAKERS:

PROF MARC BLOCKMAN, BPharm, MBChB, MMed, PGDipIntResEthics, Director, WHO Collaborating Centre for Medicines Information, Division of Clinical Pharmacology, University of Cape Town

ANDY GRAY, BPharm, MSc, FPS, FFIP, Division of Pharmacology, Discipline of Pharmaceutical Sciences, University of Kwazulu-Natal, WHO Collaborating Centre on Pharmaceutical Policy and Evidence Based Practice, Centre for the AIDS Programme of Research in South Africa (CAPRISA)

TERÉZA HOUGH, CEO, National Osteoporosis Foundation of South Africa (NOFSA), Cape Town

JOHANNA LISTER, MSc, Global Head of Health Economic Modelling, Certara, Loerrach, Germany

DR MORWEŠI MAHLANGU, MBChB, Aviation Primary Health Care, Medical Advisor, Government Employees Medical Scheme (GEMS)

SHELLEY MCGEE, BPharm, BCom, MHealthEcon, Director, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), South Africa Regional Chapter, Pretoria

JACQUI MIOT, BPharm, PhD, Division Director, Health Economics & Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg

SARVASHNI MOODLIAR, MTech Quality, HND MedTech, Manager, NHLS National QA Operations and Support Academic Affairs, Research and Quality Assurance, Sandringham, Johannesburg

JANI MUELLER, MEng, CMeRC, Director Health Technology Assessment International (HTAi), South Africa

DR NOLUTHANDO NEMATSWERANI, Head, Centre for Clinical Excellence, Discovery, Sandton

NAN OLIVIER, BPharm, BScHons, MBA, PGDipHE, Former Head, Outcomes Research, Novartis Oncology, UK

DR JACQUES R SNYMAN, MBChB, MPharmMed, MD, CEO, Independent Clinical Oncology Network (ICON), Cape Town

TIENIE STANDER, MBChB, MBA, Managing Director, TCD Research, Dubai, United Arab Emirates

PROF FRANCOIS VENTER, PhD, FCP, DTM&H, DipHIVMan, Head, Ezintsha, Wits Reproductive Health & HIV Institute, University of Witwatersrand, Johannesburg

TRYPHINE ZULU, BPharm, MScMed, MPH, Senior Manager, Disease Risk Management, Government Employees Medical Scheme (GEMS)

VENUE: University of Pretoria, Prinshof Campus, Basic Medical Sciences Building, Lecture Hall 3-6

ENQUIRIES: info@fundisa-academy.com

Satellite workshop of the 53rd Annual Conference of the South African Society for Basic and Clinical Pharmacology (SASBCP) (5-7 October 2019, Pretoria.), under the patronage of the PharmaTrain Federation.











Programme

8 OCTOBER 2	019 Worksho	P DAY 1	
09:00 - 10:45	Introduction		
09:00 - 09:15		Welcome	
09:15 - 10:45	T Wilkinson S McGee	Introduction to Pharmacoeconomics and Health Technology Assessment	
10:45 - 11:15	TEA BREAK		
11:15 - 12:45	Health Technology Ass	sessment (HTA) of Medicines in South Africa	
11:15 - 11:45		Pharmacoeconomics and National Health Insurance (NHI) perspective	
	Comparing and contrasting the approaches to the evidence on costs and effectiveness of medicines by:		
11:45 - 12:15	N Mpanza T Wilkinson	the National Department of Health Pricing Committee, including challenges during policy implementation and their implications	
12:15 - 12:45	T Stander	the pharmaceutical industry, South African case studies	
12:45 - 13:45	LUNCH BREAK		
13:45 - 15:30	HTA of Medicines in South Africa (continued)		
	Comparing and contras	sting the approaches to the evidence on costs and effectiveness of medicines by:	
13:45 - 14:00	M Blockman	the Essential Medicines List (EML) Programme	
14:00 - 14:15	S Moodliar	NHLS, cost minimisation case studies	
14:15 - 14:30	J Miot	Academic researchers	
14:30 - 14:45	N Nematswerani	the payers (Discovery)	
14:45 - 15:00	T Zulu	the payers (Government Employees Medical Scheme)	
15:00 - 15: 30	All	Discussion	
15:30 - 16:00	TEA BREAK		
16:00 - 18:00	HTA of Medicines in Other Regions		
16:00 - 16:30	N Olivier	HTA in the UK: How it works	
16:30 - 17:00	J Mueller	Recent trends and developments in the approach to HTA of medicines	
17:00 - 17:30	J Mueller	Comparison between South Africa and other regions: Political, economic and cultural factors influencing HTA	
17:30 - 18:00	All	Discussion: Relevance of international developments for the South African situation	

Programme

9 OCTOBER 2019	Workshop Day 2			
09:00 - 13:00 HTA of Medicines: New Developments				
9:00 - 10:30 J Lister	Health economic modelling to support decision making – experiences and methods from Europe and North America			
10:30 - 11:00 TEA BREA	AK			
11:00 - 11:30 T Stander	Real-world evidence and Big Data in HTA appraisals, draft EU guideline "Practical considerations when critically assessing economic evaluations"			
11:30 - 12:00 S McGee	HTA in clinical guideline development and ethical principles			
12:00 - 12:30 M Mahla	ngu New HTA technologies - GEMS perspective			
12:30 - 13:00 All	Discussion			
13:00 - 14:00 LUNCH B	REAK			
14:00 - 17:00 Interactiv	ve Session: Lessons Learnt and Future Perspectives Moderator: A Gray			
Short statements on needs and expectations by stakeholders:				
T Hough	Patients: National Osteoporosis Foundation of South Africa, NOFSA			
F Venter	Doctors			
N Nematswerani	Payers			
M Blockman	EML Programme			
T Stander	Industry			
J Miot	Academic researchers			
J Mueller	International Perspective			
N Mpanza, T Wilkinson	NDoH, Pricing Committee			
15:30 - 16:00 TEA BREAK				
	Lessons learnt in settings where HTA implementation is at an advanced stage and in those countries where traction is yet to be established, barriers to implementation and availability of essential medicines to all patients			
	Suggestions for implementation of health technology assessment for medicines in South Africa			
17:00 Conclus	sion of workshop			

HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SOUTH AFRICA

CURRENT SITUATION AND INTERNATIONAL TRENDS

8-9 October 2019

NAME AND SURNAME:				
ADDRESS:				
AFFILIATION/POSITION:				
QUALIFICATIONS:				
CONTACT DETAILS:				
EMAIL ADDRESS:				
CONTACT NUMBER:				
MEAL DEFENCE				
MEAL PREFERENCE				
NORMAL VEG	GETARIAN ALLERGIES:			
REGISTRATION FEES: 2	2 DAY WORKSHOP			
Industry, CRO's, and others R 7,500				
Academia and Government R 4,000				
Students R	1,500			
PLEASE, ENQUIRE FOR SPECIAL RA	ATES FOR GROUP REGISTRATIONS.			
ACCOUNT NAME :	Fundisa African Academy of Medicines Development			
ACCOUNT NUMBER:	9290273284			
BRANCH NAME :	ABSA Bank			
BRANCH CODE:	632005			
TYPE OF ACCOUNT :	Savings Account			
REFERENCE:	Name and Surname			

Kindly send your registration form and proof of payment to info@fundisa-academy.com

Submission deadline for registration: 30 September 2019

On completion of this application you will be liable for the full amount of the registration fees subject to the cancellation conditions below. 2.) All cancellations must be sent in writing to: Anri Jooste (info@fundisa-academy.com). 3.) Cancellations received before 15 September, 2019 will receive a refund less a 10% administration fee.
4.) No refunds will be issued for cancellation received after 15 September, 2019. 5.) All refunds due will only be issued by EFT after the Workshop. 6.) Any registrations received after 15 September, 2019 will not be entitled to any refund or credit, and such person will be liable for the full registration fee as per point (1) above. 7.) The Organizing Committee reserves the right to decline a request for refund.







